The immune response to breast cancer, and the case for DC immunotherapy

References

• Scanlan MJ, Jager D. Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res 2001;3:95–8.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82.
   PubMed Web of Science ®Google Scholar
• Tiwari RK, Borgen PI, Wong GY et al. HER-2/neu amplificationand overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 1992;12:419–25.
   PubMed Web of Science ®Google Scholar
• Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. 7 Clin Oncol 1997;15: 2894–904.
   Google Scholar
• Witters L, Engle L, Lipton A. Restoration of estrogen respon-siveness by blocking the HER-2/neu pathway. Oncol Rep 2002;9: 1163–6.
   Google Scholar
• Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamox-den resistance in breast cancer. 7 Natl Cancer Inst 2003;95:353–61.
   PubMed Web of Science ®Google Scholar
• Knowlden JM, Hutcheson IR, Jones HE et al. Elevated levels ofepidermal growth factor receptor/c-erbB2 heterodimers med-iate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003;144:1032–44.
   PubMed Web of Science ®Google Scholar
• Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999;26:78–83.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapyplus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl y Med 2001;344:783–92.
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety oftrasruzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. 7 Clin Oncol 2002;20:719–26.
   PubMed Web of Science ®Google Scholar
• zum Buschenfelde CM, Hermann C, Schmidt B et al. Antihu-man epidermal growth factor receptor 2 (HER2) monoclonal antibody trasruzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-over-expressing rumor cells. Cancer Res 2002;62:2244–7.
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Scheibenbogen C, Schaller G et al. Differences inT-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. Int 7 Cancer 2003;105: 221–5.
   Google Scholar
• Gendler SJ. MUC1, the renaissance molecule. 7Mammaly Gland Biol Neoplasia 2001;6: 339–53.
   Google Scholar
• Taylor-Papadimitriou J, Burchell JM, Plunkett T et al. MUC1and the immunobiology of cancer. 7 Mammary Gland Biol Neoplasia 2002;7:209–21.
   PubMed Web of Science ®Google Scholar
• Rahn JJ, Dabbagh L, Pasdar M et al. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91:1973–82.
   PubMed Web of Science ®Google Scholar
• Feuerer M, Beckhove P, Bai L et al. Therapy of human tumors inNOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7:452–8.
   PubMed Web of Science ®Google Scholar
• Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:292–300.
   PubMed Web of Science ®Google Scholar
• McDermott RS, Beuvon F', Pauly M et al. Tumor antigens and antigen-presenting capacity in breast cancer. Patho biology 2002;70:324–32.
   Google Scholar
• Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46–54.
   PubMed Web of Science ®Google Scholar
• Nasu S, Yagihashi A, Izawa A et al. Survivin mRNA expre-ssion in patients with breast cancer. Anticancer Res 2002;22:1839–43.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Iwamoto S, Con G et al. Expression of survivin andits relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127–34.
   PubMed Web of Science ®Google Scholar
• Choi KS, Lee TH, Jung MH. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther 2003;10: 87–95.
   Google Scholar
• Andersen MH, Pedersen LO, Capeller B et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001;61:5964–8.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick KL, Clark G, Ghilchick M et al. hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur y Surg Oncol 2003;29:321–6.
   PubMed Web of Science ®Google Scholar
• Herbert BS, Wright WE, Shay JW. Telomerase and breast cancer. Breast Cancer Res 2001;3:146–9.
   PubMed Web of Science ®Google Scholar
• Poremba C, Heine B, Diallo R et al. Telomerase as a prognosticmarker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. 7 Pathol 2002;198:181–9.
   Web of Science ®Google Scholar
• Vonderheide RH, June CH. A translational bridge to cancer immunotherapy: exploiting co-stimulation and target antigens for active and passive T cell immunotherapy. Immunol Res 2003;27:341–56.
   PubMed Web of Science ®Google Scholar
• Kontani K, Taguchi 0, Narita T et al. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br y Cancer 2001;84: 1258–64.
   Google Scholar
• Hillenbrand EE, Neville AM, Coventry BJ. Immunohistochem-ical localization of CD1a-positive putative dendritic cells in human breast rumours. Br 7 Cancer 1999;79: 940–4.
   Google Scholar
• Bell D, Chomarat P, Broyles D et al. In breast carcinoma tissue,immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. 7 Exp Med 1999;190:1417–26.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Shinohara H, Miyamoto A et al. Prognostic value oftumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int 7 Cancer 2003;104:92–7.
   PubMed Web of Science ®Google Scholar
• Coventry BJ, Lee PL, Gibbs D et al. Dendritic cell density and activation status in human breast cancer - CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br7 Cancer 2002;86:546–51.
   PubMed Web of Science ®Google Scholar
• Jakub JW, Pendas S, Reintgen DS. Current status of sentinel lymph node mapping and biopsy: facts and controversies. Oncologist 2003;8:59–68.
   Google Scholar
• Huang RR, Wen DR, Guo J et al. Selective modulation of paracortical dendritic cells and T-lymphocytes in breast cancer sentinel lymph nodes. Breast 7 2000;6:225–32.
   Google Scholar
• Morton DL. Lymphatic mapping and sentinel lymphadenect-omy for melanoma: past, present, and future. Ann Surg Oncol 2001;8:225-8S.
   Google Scholar
• Wen DR, Hoon DS, Chang C et al. Variations in lymphokine generation by individual lymph nodes draining human malig-nant rumors. Cancer Immunol Immunother 1989;30:277–82.
   PubMed Web of Science ®Google Scholar
• Leong SP, Peng M, Zhou YM et al. Cytokine profiles of sentinellymph nodes draining the primary melanoma. Ann Surg Oncol 2002;9:82–7.
   PubMed Web of Science ®Google Scholar
• Pinedo HM, Suter J, Luykx-de Bakker SA et al. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSE effect on rumour-draining lymph node dendritic cells. Eur 7 Cancer 2003;39: 1061–7.
   Google Scholar
• Gabrilovich DI, Corak J, Ciernik IF et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3:483–90.
   PubMed Web of Science ®Google Scholar
• Sledge GW Jr. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002;29:104–10.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human rumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096–103.
   PubMed Web of Science ®Google Scholar
• Linehan DC, Goedegebuure PS, Peoples GE et al. Tumor-specific and HLA-A2-restricted cytolysis by rumor-associated lymphocytes in human metastatic breast cancer. 7 Immunol 1995;155: 4486–91.
   Google Scholar
• Baxevanis CN, Dedoussis GV, Papadopoulos NG et al. Tumor specific cytolysis by rumor infiltrating lymphocytes in breast cancer. Cancer 1994;74:1275–82.
   PubMed Web of Science ®Google Scholar
• Schirrmacher V. T-cell immunity in the induction and main-tenance of a tumour dormant state. Semin Cancer Biol 2001;11:285–95.
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Feuerer M, Beckhove P et al. T cell memory, anergy and immunotherapy in breast cancer. 7 Mammaly Gland Biol Neoplasia 2002;7:201–8.
   PubMed Web of Science ®Google Scholar
• Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. 7 Natl Cancer Inst 1999;91: 80–5.
   Google Scholar
• Menard S, Tomasic G, Casalini P et al. Lymphoid infiltration asa prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997;3:817–9.
   PubMed Web of Science ®Google Scholar
• Demaria S, Volm MD, Shapiro RL et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001;7:3025–30.
   PubMed Web of Science ®Google Scholar
• Camp BJ, Dyhrman ST, Memoli VA et al. In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Oncol 1996;3:176–84.
   PubMed Web of Science ®Google Scholar
• Venetsanakos E, Beckman I, Bradley J et al. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast rumours. Br y Cancer 1997;75:1826–30.
   PubMed Web of Science ®Google Scholar
• Marrogi AJ, Munshi A, Merogi AJ et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int 7 Cancer 1997;74:492–501.
   PubMed Web of Science ®Google Scholar
• Shevach EM. CD4± CD25± suppressor T cells: more questionsthan answers. Nat Rev Immunol 2002;2:389–400.
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25± CD4± T cells: a common basis between rumor immunity and autoimmunity. 7 Immunol 1999;163: 5211–8.
   Google Scholar
• Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatoryT cells is increased in peripheral blood and rumor microenvir-onment of patients with pancreas or breast adenocarcinoma. Immunol 2002;169:2756–61.
   Web of Science ®Google Scholar
• Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human rumours. Immunol Today 1997;18:89–95.
   PubMedGoogle Scholar
• Cabrera T, Angustias Fernandez M, Sierra A et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996;50:127–34.
   PubMed Web of Science ®Google Scholar
• Vitale M, Rezzani R, Rodella L et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998;58:737–42.
   PubMed Web of Science ®Google Scholar
• Reichmann E. The biological role of the Fas/FasL system duringtumor formation and progression. Semin Cancer Biol 2002;12:309–15.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 2002;12:43–50.
   PubMed Web of Science ®Google Scholar
• Gutierrez LS, Eliza M, Niven-Fairchild T et al. The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat 1999;54:245–53.
   PubMed Web of Science ®Google Scholar
• Sheen-Chen SM, Chen HS, Eng HL et al. Circulating soluble Fas in patients with breast cancer. World y Surg 2003;27:10–3.
   PubMed Web of Science ®Google Scholar
• Mor G, Kohen F, Garcia-Velasco J et al. Regulation of fas ligandexpression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. 7 Steroid Biochem Mol Biol 2000;73:185–94.
   PubMed Web of Science ®Google Scholar
• Coveney E, Wheatley GH, 3rd, Lyerly HK. Active immuniza-tion using dendritic cells mixed with rumor cells inhibits the growth of primary breast cancer. Surgery) 1997;122:228–34.
   Google Scholar
• Bai L, Beckhove P, Feuerer M et al. Cognate interactions between memory T cells and tumor antigen-presenting den-dritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo. Int y Cancer 2003;103:73–83.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Shinohara H, Toyoda M et al. Regression of lymphnode metastases by immunotherapy using autologous breast tumor-lysate pulsed dendritic cells: report of a case. Surg Today 2001;31:513–6.
   PubMed Web of Science ®Google Scholar
• Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369— 377) from HER-2/neu leads to peptide-specific cyto-toxic T lymphocytes that fail to recognize HER-2/neu tumors. Cancer Res 1998;58:4902–8.
   PubMed Web of Science ®Google Scholar
• Disis ML, Grabstein KH, Sleath PR et al. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289–97.
   PubMed Web of Science ®Google Scholar
• Dong J, McPherson CM, Stambrook PJ. Flt-3 ligand: a potentdendritic cell stimulator and novel antitumor agent. Cancer Biol Ther 2002;1: 486–9.
   Google Scholar
• Disis ML, Rinn K, Knutson KL et al. F1t3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 2002;99:2845— 50.
   PubMed Web of Science ®Google Scholar
• Morse MA, Clay TM, Colling K et al. HER2 dendritic cell vaccines. Clin Breast Cancer 2003;3(Suppl 4):S164–72.
   Google Scholar
• Brossart P, Wirths S, Sruhler G et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102— 8.
   PubMed Web of Science ®Google Scholar
• Morse MA, Deng Y, Coleman D et al. A Phase I study of activeimmunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic anti-gen. Clin Cancer Res 1999;5:1331— 8.
   PubMed Web of Science ®Google Scholar
• Chen Y, Emtage P, Zhu Q et al. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther 2001;8:316–23.
   PubMed Web of Science ®Google Scholar
• Pecher G, Haring A, Kaiser L et al. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 2002;51:669–73.
   PubMed Web of Science ®Google Scholar
• Heiser A, Coleman D, Dannull J et al. Autologous dendritic cellstransfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate rumors. 7 Clin Invest 2002;109:409— 17.
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003;63:2127–33.
   PubMed Web of Science ®Google Scholar
• Morse MA, Nair SK, Boczkowski D et al. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int 7 Gastrointest Cancer 2002;32:1— 6.
   PubMed Web of Science ®Google Scholar
• Muller MR, Grunebach F, Nencioni A et al. Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. 7 Immunol 2003;170:5892 — 6.
   PubMed Web of Science ®Google Scholar
• Gong J, Avigan D, Chen D et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 2000;97:2715— 8.
   PubMed Web of Science ®Google Scholar
• Xia J, Tanaka Y, Koido S et al. Prevention of spontaneous breastcarcinoma by prophylactic vaccination with dendritic/rumor fusion cells. 7 Immunol 2003;170:1980— 6.
   PubMed Web of Science ®Google Scholar
• Chen D, Xia J, Tanaka Y et al. Immunotherapy of spontaneousmammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 2003;109:300–7.
   PubMed Web of Science ®Google Scholar
• Avigan D. Fusions of breast cancer and dendritic cells as a novelcancer vaccine. Clin Breast Cancer 2003;3(Suppl 4):S158–63.
   Google Scholar